{
    "nct_id": "NCT04511845",
    "official_title": "A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "(Both Part I and Part II)\n\n* Age >= 18 years at time of signing informed consent form\n* ECOG performance status of 0 or 1\n* Patients with a locally advanced, recurrent, or metastatic solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable\n\n(Part I only)\n\n* Patients with measurable and/or evaluable disease per RECIST v1.1\n* Patients with MAPK pathway alterations positive solid tumor (i.e., BRAF, K/N/H-RAS mutations)\n\n(Part II only)\n\n* Patients with measurable disease per RECIST v1.1\n* Patients with KRAS mutated NSCLC (NSCLC cohort)\n* Patients with KRAS mutated Ovarian Cancer (Ovarian Cancer cohort)\n* Patients with RAS mutated solid tumor (Biopsy cohort)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "(Both Part I and Part II)\n\n* Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months\n* Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases\n* Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection)\n* Patients with a history or complication of interstitial lung disease (ILD)",
    "miscellaneous_criteria": ""
}